RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
1-Year Return
12.81%
This Quarter Return
+4.94%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$977M
AUM Growth
+$166M
(+20%)
Cap. Flow
+$140M
Cap. Flow
% of AUM
14.32%
Top 10 Holdings %
Top 10 Hldgs %
25.96%
Holding
96
New
4
Increased
44
Reduced
31
Closed
7
Top Buys
| 1 |
Nektar Therapeutics
NKTR
|
$20M |
| 2 |
WBA
Walgreens Boots Alliance
WBA
|
$15.3M |
| 3 |
Incyte
INCY
|
$15.1M |
| 4 |
AET
Aetna Inc
AET
|
$12.8M |
| 5 |
Sangamo Therapeutics
SGMO
|
$11.3M |
Top Sells
| 1 |
AbbVie
ABBV
|
$12.7M |
| 2 |
Biogen
BIIB
|
$8.5M |
| 3 |
CELG
Celgene Corp
CELG
|
$6.81M |
| 4 |
ABMD
Abiomed Inc
ABMD
|
$6.58M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$6.21M |
Sector Composition
| 1 | Healthcare | 91.68% |
| 2 | Financials | 1.43% |
| 3 | Energy | 0.15% |
| 4 | Technology | 0.13% |
| 5 | Communication Services | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Esperion Therapeutics
ESPR
$500M
| $15.9M | 1.63% |
406,361
+161,821
| +66% | +$6.34M |
|
|
SGEN
27
DELISTED
Seagen Inc. Common Stock
SGEN
| $15.3M | 1.56% |
230,000
+100,000
| +77% | +$6.64M |
|
28
FibroGen
FGEN
$46.9M
| $15M | 1.53% |
9,582
+2,800
| +41% | +$4.38M |
|
|
29
Sangamo Therapeutics
SGMO
$162M
| $14.9M | 1.53% |
1,051,933
+796,140
| +311% | +$11.3M |
|
|
ONCE
30
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $14.7M | 1.5% |
177,600
+110,000
| +163% | +$9.1M |
|
31
Glaukos
GKOS
$5.23B
| $14.6M | 1.5% |
360,000
-143,400
| -28% | -$5.83M |
|
32
NovoCure
NVCR
$1.35B
| $14.1M | 1.44% |
450,000
+15,000
| +3% | +$470K |
|
33
Agios Pharmaceuticals
AGIO
$2.09B
| $13.5M | 1.38% |
160,428
+65,428
| +69% | +$5.51M |
|
|
PTLA
34
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $13.3M | 1.36% |
352,302
+82,054
| +30% | +$3.1M |
|
35
Abbott
ABT
$231B
| $12.9M | 1.32% |
212,000
+10,000
| +5% | +$610K |
|
|
AET
36
DELISTED
Aetna Inc
AET
| $12.8M | 1.31% |
+70,000
| New | +$12.8M |
|
|
ARNA
37
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $12.4M | 1.27% |
284,621
-1,021
| -0.4% | -$44.5K |
|
|
ITCI
38
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $12.3M | 1.26% |
696,957
-95,773
| -12% | -$1.69M |
|
|
ARRY
39
DELISTED
Array Biopharma Inc
ARRY
| $12.1M | 1.24% |
723,370
+21,900
| +3% | +$367K |
|
40
Alkermes
ALKS
$4.78B
| $11.9M | 1.22% |
290,000
+199,200
| +219% | +$8.2M |
|
41
Boston Scientific
BSX
$160B
| $11.4M | 1.16% |
347,968
| – | – |
|
42
Alnylam Pharmaceuticals
ALNY
$59.5B
| $11.2M | 1.15% |
113,967
+30,000
| +36% | +$2.95M |
|
43
Iovance Biotherapeutics
IOVA
$778M
| $10.8M | 1.11% |
847,476
-96,709
| -10% | -$1.24M |
|
44
Neurocrine Biosciences
NBIX
$13.7B
| $10.8M | 1.11% |
110,377
+377
| +0.3% | +$37K |
|
|
IMMU
45
DELISTED
Immunomedics Inc
IMMU
| $10.8M | 1.1% |
455,330
+40,000
| +10% | +$947K |
|
46
Cencora
COR
$56.9B
| $10.6M | 1.08% |
124,261
+20,000
| +19% | +$1.71M |
|
47
Edwards Lifesciences
EW
$47.4B
| $9.95M | 1.02% |
205,092
-45,000
| -18% | -$2.18M |
|
|
MYOK
48
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $9.84M | 1.01% |
198,272
+30,000
| +18% | +$1.49M |
|
|
FLXN
49
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $9.09M | 0.93% |
351,786
+115,100
| +49% | +$2.98M |
|
50
LivaNova
LIVN
$3.15B
| $8.49M | 0.87% |
85,000
+35,000
| +70% | +$3.49M |
|